Showing 3541-3550 of 9296 results for "".
- FDA Approves Otezla to Treat Psoriatic Arthritishttps://practicaldermatology.com/news/20140321-fda_approves_otezla_to_treat_psoriatic_arthritis/2459301/The FDA approved Otezla ( Celgene, apremilast) to treat adults with active psoriatic arthritis (PsA).“Relief of pain and inflammation and improving physical function are important treatment goals for patients with active psoriatic arthritis,” said Curtis Rosebraugh, M.D., M.P.H., director of…
- Pollogen to Launch FDA-Cleared Imogen at AAD Annual Meetinghttps://practicaldermatology.com/news/20140318-pollogen_to_launch_fda-cleared_imogen_at_aad_annual_meeting/2459312/Pollogen Ltd., will launch its Imogen system in the United States during the upcoming American Academy of Dermatology (AAD) meeting in Denver. The Imogen System is FDA cleared for dermatological procedures requiring ablation and resurfacing of the skin using the VoluDerm appli…
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic treatment of facial erythema of rosacea in adul…
- Promius Pharma, LLC Introduces Dr. Reddy's Authorized Generic Producthttps://practicaldermatology.com/news/20140225-promius_pharma_llc_introduces_dr_reddys__authorized_generic_product/2459331/Promius Pharma, LLC, launched its first Authorized Generic (AG) of Cloderm® Cream through its parent company Dr. Reddy's Laboratories on February 14. The AG is identical in formulation to Cloderm® Cream and will provide all the similar benefits, while increasing access and reducing pharmacy call b…
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our next Phase…
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, before…
- Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Millionhttps://practicaldermatology.com/news/20140203-valeant_pharmaceuticals_to_acquire_precision_dermatology_for_475_million/2459351/Valeant Pharmaceuticals International, Inc. has entered into a definitive agreement to acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high qual…
- Acella Pharmaceuticals Announces Approval and Launch of Loutrex Topical Creamhttps://practicaldermatology.com/news/20140131-acella_pharmaceuticals_announces_approval_and_launch_of_loutrex_topical_cream/2459352/Acella Pharmaceuticals, LLC, launched Loutrex Topical Cream following a successful 510(k) notification with FDA, which determined that Acella's 510(k) submission was equivalent to another legally U.S.-marketed device and at least as safe and effective as the predicate. Loutre…
- Curt Cole Wins "Best Presentation of the Day" and Lifetime Achievement Awards at Winter Clinical Dermatology Conferencehttps://practicaldermatology.com/news/20140128-curt_cole_wins_best_presentation_of_the_day_and_lifetime_achievement_awards_at_winter_clinical_dermatology_conference/2459357/"Beyond Broad Spectrum: Critical Concepts in a Post-Monograph World " - a podium presentation by photobiologist and industry veteran Curtis Cole, Ph.D, - was voted "Best Presentation of the Day," Tuesday, January 21 at the Winter Clinical Dermatology Conference. Given the broad scope of topics and…
- Everett Laboratories Acquires Quinnova Pharmaceuticalshttps://practicaldermatology.com/news/20140123-everett_laboratories_acquires_quinnova_pharmaceuticals/2459363/Everett Laboratories, Inc., a privately held specialty pharmaceutical company and a subsidiary of Exeltis, headquartered in Madrid, Spain, today announced that it has acquired Quinnova Pharmaceuticals, Inc. from parent company Amneal Enterprises, LLC. …